What is the market's earnings forecast for agilon health next quarter?

What were the key takeaways from agilon health’s earnings call?

What were the key takeaways from agilon health's earnings call?

What is the revenue and EPS growth rate for agilon health year over year?

What is agilon health's latest dividend and current dividend yield?

What factors drove the changes in agilon health's revenue and profit?

What does agilon health do and what are its main business segments?

Did agilon health beat or miss consensus estimates last quarter?

- **2026 Financial Reset**: Targets $300-350M medical margin, breakeven adj. EBITDA, and 7.5% cost trend. 
- **Strategic Restructuring**: Exited 50,000 unprofitable members, 25,000 moved to fee-for-service with upside. 
- **Clinical Impact**: CHF pathways reduce inpatient costs, AI-driven risk ID improves margin by 40bps. 
- **CMS Risk Mitigation**: BOI program 99%+ accurate, minimal exposure to unlinked coding. 
- **Quality Growth**: 2026 quality incentive opportunity >$100M, 4.2+ star rating target.

**【Management Opening Remarks】**
- **2025 Progress**: Focused on operational discipline, exiting unprofitable contracts, and reducing membership to 430,000 (down 50,000) to prioritize profitability. 
- **Strategic Shifts**: Transitioned 25,000 members to care coordination fee models with upside incentives, reducing Part D exposure to <15%.
- **Clinical Initiatives**: Expanded CHF pathways to 90% of network, palliative care engagement, and AI-driven high-risk member identification.
- **2026 Outlook**: Target medical margin of $300-350M, breakeven adjusted EBITDA, and $5.41-5.58B revenue. 

**【CFO Financial Commentary】**
- **2025 Results**: Full-year revenue $5.93B, medical margin -$57M, adj. EBITDA -$296M. Q4 cost trend 7.4% (up from 6.5% YoY). 
- **2026 Guidance**: 7.5% gross cost trend, $35M opex savings, and $625M incremental value from disciplined contracting. 
- **Liquidity**: $285M cash at year-end, $125M+ expected in 2026. 

**【Q&A Highlights】**
- **Cost Trend Concerns**: Q3 inpatient spikes ($6.5M+ claims) drove 7.2% trend, prudent 7.4% Q4 assumption. 2026 trend assumes 7.5% gross, 7% net. 
- **CMS Rate Notice**: Disappointed with 2027 risk model, but confident BOI and pathways (e.g., CHF) will mitigate impact. 
- **Quality Incentives**: 2026 quality bonus opportunity >$100M, targeting 4.2+ star rating. 
- **LEAD Program**: Viewing as long-term growth opportunity, aligning with CMS's 10-year model focus on high-need patients.

Agilon Health, Inc.(AGL)-20260226-2025 Q4 Earnings call transcript

- **2025 Q3 Results**: $1.44B revenue (-1.4% YoY), -$57M medical margin
- **2026 Outlook**: 6.5% cost trend, $30M cost savings
- **Contract Renegotiation**: 50% of contracts updated for better economics
- **AI Success**: 20% reduction in heart failure admissions
- **Stars Performance**: 75% of members in 4-star plans

**【CEO Summary Section】**
- Agilon reported Q3 2025 revenue of $1.44 billion, reflecting a 1.4% year-over-year decline due to lower-than-expected risk adjustment scores and exited markets.
- The company is implementing a $30 million cost reduction plan, including overhead and clinical incentives, to improve 2026 margins.
- Agilon is renegotiating contracts with payers to reduce Part D exposure and increase quality incentives, with 75% of members in 4-star plans.

**【CFO Financial Commentary】**
- Q3 medical margin was -$57 million, driven by exited markets and oncology costs.
- Adjusted EBITDA was -$91 million, improved from -$96 million in Q2.
- 2025 guidance: $5.8 billion revenue, -$245 million EBITDA.

**【Q&A Highlights】**
- 2026 contracting: 50% of contracts renegotiated for better economics; 75% of members in 4-star plans.
- AI-driven programs reduced heart failure admissions by 20%.
- 2026 cost trend outlook: 6.5% in line with CMS benchmarks.

agilon health, inc. (AGL) Q3 2025 Earnings Call Transcript

- **Q2 Underperformance**: Revenue down 5% YoY to $1.4B, driven by $66M negative prior period risk adjustment and $48M 2025 true-up. Medical margin negative due to unfavorable Part D costs.
- **Strategic Shifts**: Enhanced data platform (72% membership coverage), AI-driven clinical pathways, and quality programs to reduce variability. 2026 focus on contract renegotiation, Part D carve-out, and Medicare rate leverage.
- **Leadership Transition**: Ron Williams as Executive Chairman driving urgency; Office of the Chairman formed to accelerate execution. CEO search underway for operational rigor and payer expertise.
- **2026 Outlook**: Positive rate environment and clinical program expansion expected to enhance profitability. Liquidity sufficient to navigate challenges while optimizing performance.

**【Management Opening Remarks】**
- **Underperformance Acknowledgment**: Ron Williams highlighted Q2 underperformance due to lower-than-expected 2024 risk adjustment baseline and 2025 risk adjustment trending below expectations. Challenges included unfavorable Part D developments and delayed physician engagement.
- **Strategic Initiatives**: Launched enhanced data platform, AI-driven clinical pathways (e.g., heart failure, COPD), and quality programs to reduce variability and improve outcomes. 72% of membership now on enhanced data platform, showing high correlation between 2024 and mid-2025 data.
- **Leadership Changes**: Transition to Executive Chairman role, forming Office of the Chairman to drive urgency and accountability. Daily leadership meetings to accelerate execution and improve performance.
- **2026 Outlook**: Focus on improving contract economics, reducing Part D exposure (below 30% in 2025), and leveraging new Medicare rates. Expect enhanced data visibility to improve forecasting and performance.

**【CFO Financial Commentary】**
- **Q2 Financials**: Total revenue $1.4B (-5% YoY), medical margin -$53M (vs. +$106M YoY), adjusted EBITDA -$83M (vs. -$3M YoY). Key drivers: $66M negative prior period development (2024 risk adjustment), $48M 2025 risk adjustment true-up, and unfavorable Part D costs.
- **Cost Trends**: Year 2+ markets medical cost trend 5.9% (flat YoY). Inpatient and Part B (oncology drugs) driving costs. 2025 guidance withdrawn due to market uncertainty.
- **Liquidity**: $327M cash and $176M off-balance sheet ACO cash. Sufficient liquidity to navigate challenges while focusing on 2026 profitability.

**【Q&A Highlights】**
- **2026 Bidding**: Payers seeking improved economics; 50% of 2026 contracts up for renewal. Focus on reducing Part D exposure, expanding quality incentives, and aligning risk with value delivered.
- **Risk Adjustment Variability**: 72% of membership on enhanced data platform; remaining 28% await midyear 2025 risk scores. Variability by payer complicates extrapolation.
- **CEO Search**: Seeking leader with multi-market management experience, payer relationships, and operational rigor. No immediate plans to exit markets, but continuous evaluation of profitability.
- **Quality Incentives**: Strong performance in year 2+ markets (≥4.25 stars). Payers increasing dollars at risk for quality, aligning with agilon's strengths.
- **ACO REACH Performance**: Q2 EBITDA $10M, tracking to full-year expectations. Program stability and growth continue.


Agilon Health (AGL)-4 Aug 25-2025 Q2 Earnings call transcript

- **Q1 2025 Performance Stable:** Results in line with guidance amid cautious growth (3% same-geography expansion) and elevated cost trends (5.3% FY25 medical cost trend). 
- **2026 CMS Rate Boost:** 280bps rate increase provides tailwind, but 50% of 2026 membership up for renewal with focus on reducing Part D exposure (<30% of members). 
- **Clinical Program Impact:** Palliative care reduces hospital admissions by 30%; heart failure pathway shows early promise in preventing ER admissions. 
- **Cash Position Solid:** $369M cash on hand with $110M expected 2025 usage. 
- **2027 Growth Pipeline:** 30,000-45,000 new members expected, driven by demand for value-based care partnerships. 


**【CEO Opening Remarks】**
- Q1 2025 results in line with guidance: membership (491,000), revenue ($1.53B), medical margin ($128M), and adjusted EBITDA ($21M). 
- Membership flat YoY due to cautious growth strategy (3% same-geography expansion) and exits of underperforming partnerships. 
- 2026 CMS rate increase of 280bps provides tailwind, but elevated cost trends (5.3% FY25 medical cost trend) remain a challenge. 
- Investments in AI-driven clinical pathways (e.g., heart failure program) and palliative care show early promise in reducing hospitalizations and improving outcomes. 
- 50% of 2026 membership up for renewal, with focus on reducing Part D exposure (<30% of members) and negotiating quality incentives. 

**【CFO Financial Update】**
- Q1 2025 financials: 
  - Total revenue: $1.53B (down 5% YoY) 
  - Medical margin: $128M (down 19% YoY) 
  - Adjusted EBITDA: $21M (down 28% YoY) 
- Key drivers: 
  - Elevated inpatient costs (+flu impact) 
  - Negative prior period development ($22M) 
  - Improved visibility via new financial data pipeline 
- 2025 guidance: 
  - Membership: 490,000-520,000 
  - Revenue: $5.85B-$6.03B 
  - Medical margin: $275M-$325M 
  - Adjusted EBITDA: -$95M to -$55M 
- Cash position: $369M (including $25M off-balance-sheet) with $110M expected cash usage for 2025. 

**【Q&A Highlights】**
- **Risk Model Transition (V-28):** 2% net risk score increase YoY, in line with expectations. Primary care continuity drives stability. 
- **2026 MA Rate Cycle:** 40% of membership repriced with CMS rate increase; 50% of 2026 membership up for renewal with focus on: 
  1. Reducing Part D exposure (1 payer carved out for 2026) 
  2. Quality incentives (4.25+ star performance) 
  3. Clinical cost savings (palliative care program expansion) 
- **Part D Management:** <30% of members retain Part D risk; 2025 benefit design changes reduce exposure for 97% of membership. 
- **Clinical Program Progress:** 
  - Palliative care: 30% reduction in hospital admissions per 1,000 members 
  - Heart failure pathway: early detection reducing ER admissions 
- **Humana Star Rating Concerns:** Offset through increased percentage of premium and lump-sum payments; strong quality performance (4.25+ stars) provides differentiation. 
- **2027 Growth Pipeline:** 30,000-45,000 new members expected, focused on same-geography growth and value-based care partnerships. 


agilon health (AGL)-6 May 25-2025 Q1 Earnings call transcript

- **Membership Strategy**: 2025 MA membership decline to 505,000 (midpoint) reflects risk reduction, with 2026 class of 30,000-45,000.
- **Financial Targets**: 2025 medical margin $300M (+46% YoY), adjusted EBITDA -$75M, driven by 6.3% cost trend and $50M operating initiatives.
- **Part D Risk Mitigation**: <30% of 2025 membership exposed, with PMPM loss doubled due to regulatory changes.
- **Long-Term Vision**: 2027 cash flow breakeven target, with CMS 2026 advance notice signaling potential rate improvements.

**【CEO Opening Remarks】**
- **2024 Performance Overview**: MA membership grew 36% YoY to 527,000, driven by the 2024 partner class and 4.1% same-geography growth. Total revenue increased 44% to $1.52B, with medical margin of $1M in Q4 and $205M annually.
- **2025 Strategic Adjustments**: Membership expected to decline 4% YoY to 505,000 (midpoint), with a smaller 2025 partner class of 20,000. Focus on reducing exposure to uncontrollable costs (e.g., Medicare Part D <30% of membership) and maintaining disciplined growth.
- **Long-Term Vision**: Target cash flow breakeven by 2027, with 2026 CMS advance notice signaling potential rate improvements. Emphasizes clinical programs (e.g., palliative care, chronic disease management) to drive quality and cost savings.

**【CFO Financial Details】**
- **Q4 2024 Results**: GAAP revenue $1.52B, medical expense $1.52B, medical margin $1M. Adjusted EBITDA loss $84M, driven by elevated Part D costs ($6M) and underperforming MSSP contracts.
- **2025 Guidance**: 
  - MA membership: 505,000 (midpoint), ACO model 110,000.
  - Revenue: $5.925B (-2% YoY), medical margin $300M (+46% YoY).
  - Adjusted EBITDA: -$75M (midpoint), reflecting 6.3% gross medical cost trend and $50M operating initiatives.
- **Cash Flow Management**: Ended Q4 with $406M cash, expecting $110M cash use in 2025. Improved working capital and payor contract terms (e.g., upfront premium payments) reduced cash burn.

**【Q&A Key Highlights】**
- **Part D Risk Reduction**: Reduced to <30% of 2025 membership, with PMPM loss doubled due to Inflation Reduction Act. 40% of 2025 membership repriced with improved economic terms.
- **2025 Member Growth**: Smaller 20,000-member partner class with glide-path contracts (no downside in Year 1). 2026 class of 30,000-45,000 reflects measured expansion.
- **Medical Cost Trends**: 6.3% gross trend for 2025, down from 6.8% in 2024, driven by payor bid adjustments and reduced supplemental benefits risk.
- **ACO REACH Performance**: 2024 savings $150M, targeting $35-40M EBITDA in 2025. MSSP exit for underperforming partnership.
- **2026 Outlook**: CMS advance notice signals potential rate improvements, but final notice needed for clarity. Focus on quality-driven contracts and reduced business risk.

Actual	-0.045	-0.79	-0.09	-0.14	0.0029	-0.05	-0.07	-0.14	0.04	-0.04	-0.08	-0.41	0.01	-0.07	-0.29	-0.26	0.0293	-0.25	-0.27	-0.46
Forecast	-0.0298	-0.0531	-0.085	-0.1055	-0.0006	-0.0168	-0.0451	-0.0971	0.035	-0.0183	-0.0543	-0.277	-0.0127	-0.0703	-0.0986	-0.2169	-0.003	-0.1092	-0.1494	-0.2719
Surprise	-51.01%	-1387.76%	-5.88%	-32.70%	+583.33%	-197.62%	-55.21%	-44.18%	+14.29%	-118.58%	-47.33%	-48.01%	+178.74%	+0.43%	-194.12%	-19.87%	+1076.67%	-128.94%	-80.72%	-69.18%

AGL

AGL fundamentals

AGL Q4 2025 Earnings

Earnings Call

You can ask Aime

AGL

AGL fundamentals

AGL Q4 2025 Earnings

Earnings Call

AGL Earnings Call Summary for Q4/20254:30 PM on Feb 25, 2026

AGL Earnings Call Summary for Q3/20254:30 PM on Nov 4, 2025

AGL Earnings Call Summary for Q2/20255:30 PM on Aug 4, 2025

AGL Earnings Call Summary for Q1/20254:30 PM on May 6, 2025

AGL Earnings Call Summary for Q4/20244:30 PM on Feb 25, 2025

You can ask Aime